Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis
Tamás Tornai(University of Debrecen), Mária Papp(University of Debrecen), Eszter Pályu(University of Debrecen), Dávid Tornai(Beth Israel Deaconess Medical Center), Alajos Pár(University of Debrecen), Gábor Veres(Southwest General Health Center), Gabriella Pár(University of Debrecen), Zakera Shums(Nova Medical (United States)), Péter Antal‐Szalmás(University of Debrecen), Péter Orosz(University of Debrecen), Antal Dezsőfi(Semmelweis University), Gary L. Norman(Nova Medical (United States)), Zsuzsanna Vitális(Semmelweis University), István Tornai(University of Debrecen), Ferenç Szalay(University of Debrecen), Péter L. Lakatos(McGill University)
Cited by 48
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
|Science|2009|1.5k
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
|Journal of Pediatric Gastroenterology and Nutrition|2013|1.4k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k